David Mathai, MD

🌿 Medical Director, Psychiatry, Sattva Medicine
🔬 Psychedelic Therapy Researcher
📚 Baylor College of Medicine

You and your experience matter.

[David Mathai, MD @d_mathai]

🚨 New publication from our group! "Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study" @BCMEthics

[David Mathai, MD @d_mathai]

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3): https://t.co/nkb3pQl1R2

[Dr. Rick Barnett, PsyD 😊 @drrickbarnett]

Reported Safety Practices of Publicly Advertised Psychedelic Retreats https://t.co/6Ke44dMm0t
I find this study could be a useful springboard for deep discussions around safety and ethics, but NOT only from a western medical lens.

[JAMA Network Open @JAMANetworkOpen]

Across #PsychedelicRetreats, most organizations conducted medical history screening and recommended medication washout, but safety protocols and health professional involvement varied. https://t.co/dMAnMJ5Iix

[David Mathai, MD @d_mathai]

🚨 New publication led by the OSU psychedelic center! "𝗨𝗦 𝗱𝗿𝘂𝗴 𝗽𝗼𝗹𝗶𝗰𝘆 𝗱𝗼𝗲𝘀 𝗻𝗼𝘁 𝗮𝗹𝗶𝗴𝗻 𝘄𝗶𝘁𝗵 𝗲𝘅𝗽𝗲𝗿𝘁𝘀’ 𝗿𝗮𝗻𝗸𝗶𝗻𝗴𝘀 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗵𝗮𝗿𝗺𝘀: 𝗔 𝗺𝘂𝗹𝘁𝗶-𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀" https://t.co/P2nVKOkxMk

[David Mathai, MD @d_mathai]

DISCLAIMER: This post is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions related to mental health or treatment options.

[David Mathai, MD @d_mathai]

🚨 New publication from our group! "Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study" @BCMEthics

[David Mathai, MD @d_mathai]

Link to the pre-proof version of the article: https://t.co/BPghw9cDoo

[BCM Ethics & Policy @BCMEthics]

🚨 New paper alert! 🚨 Check out the latest viewpoint by our Dr. McGuire, scholar Dr. Mathai, and collaborators on minimizing risk and harm in the use of psychedelics.

Read more: https://t.co/JVznq7KczL

#Psychedelics #HarmReduction

[David Mathai, MD @d_mathai]

@DocDurDur @unlimited_sci Thanks for asking! We bring this useful point up in the discussion. While we didn't look at state shame at baseline, the scores we found with psilocybin were consistent with those seen in other shame-activating experimental paradigms and higher than those seen without activation

[Shayla Love @shayla__love]

Lots of people have been speculating about Elon Musk’s ketamine use, and so I wrote about what we do know about prolonged, heavy ketamine use in samples of recreational users. Many of these risks are well-known already in psychedelic circles. https://t.co/Wi5sBIKmKe

[DoubleBlind @doubleblindmag]

Today in The Drop In: Beat-era poet and artist Gerd Stern’s final chapter, new research on why guilt during a trip might actually help you heal, and monkeys tapping into plant medicine. Plus, soul retrieval and what to know before working with Datura.

https://t.co/RLPEHHOEAT

[Journal of Studies on Alcohol and Drugs @JSADJournal]

“Bad trips” and guilt: Why difficult feelings during psychedelic use might actually be a good thing: Study
@d_mathai @sdpnayak @n_sepeda @Drug_Researcher @JHPsychedelics @BCMEthics @unlimited_sci
https://t.co/Pt1uhUQAwb

[Johns Hopkins Psychedelic Research Center @JHPsychedelics]

New publication in the Journal of Psychoactive Drugs led by Dr. David Mathai (@d_mathai) exploring emotions of shame and guilt that may arise during someone's psilocybin experience, and their relevance to psychological outcomes. https://t.co/yHVtb1bT0C

[BCM Ethics & Policy @BCMEthics]

Excited to share our health policy scholar Dr. Mathai & collabs' new paper📄✨ "Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World #Psilocybin Use"🧠🌿 #Psychedelics #MentalHealth

https://t.co/16BpMetDfJ

[David Mathai, MD @d_mathai]

A brief but necessary piece! Grateful to have contributed to this viewpoint with @JulesEvans11 and team.

[David Mathai, MD @d_mathai]

ResearchGate link: https://t.co/3Wf1iHhVYN

[David Mathai, MD @d_mathai]

NEW ARTICLE OUT: Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use https://t.co/0FegCePVlv

[Johns Hopkins Psychedelic Research Center @JHPsychedelics]

New paper published in Nature Scientific Reports, in collaboration with colleagues at Columbia and Baylor! This paper describes knowledge and attitudes surrounding therapeutic use of psilocybin and MDMA among a convenience sample of 879 U.S. healthcare professionals, including nurses, physicians, and therapists. Respondents were generally favorable towards therapeutic use and continued research on psilocybin and MDMA, though expressed some concerns including lack of trained providers to deliver these interventions and associated financial cost and accessibility issues. Interestingly, attitudes were consistently more positive regarding psilocybin than MDMA. https://t.co/jkQWW9Oft9

[Michael Pollan @michaelpollan]

DEA concludes hearing on 2 psychedelic research compounds; healthcare professionals enthusiastic but not so knowledgeable about MDMA & psilocybin; New association for “prescription psychedelics" https://t.co/rMApdzUgGb